Paying users zone. Data is hidden behind: .
Get 1-month access to Edwards Lifesciences Corp. for $13.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Edwards Lifesciences Corp. pages available today for free:
Analysis of Liquidity Ratios
Quarterly Data
Liquidity ratios measure the company’s ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Edwards Lifesciences Corp., liquidity ratios (quarterly data)
Based on: 10-K (filing date: 2021-02-12), 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29).
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Edwards Lifesciences Corp.’s current ratio improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020. |
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Edwards Lifesciences Corp.’s quick ratio improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020. |
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Edwards Lifesciences Corp.’s cash ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Current Ratio
Edwards Lifesciences Corp., current ratio calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Current assets | ||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||
Current ratio1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Current Ratio, Competitors2 | ||||||||||||||||||||||||||
Becton, Dickinson & Co. | ||||||||||||||||||||||||||
Boston Scientific Corp. | ||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
Stryker Corp. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (filing date: 2021-02-12), 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29).
1 Q4 2020 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Edwards Lifesciences Corp.’s current ratio improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020. |
Quick Ratio
Edwards Lifesciences Corp., quick ratio calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Cash and cash equivalents | ||||||||||||||||||||||||||
Short-term investments | ||||||||||||||||||||||||||
Accounts receivable, net of allowances | ||||||||||||||||||||||||||
Other receivables | ||||||||||||||||||||||||||
Accounts and other receivables, net of allowances (legacy) | ||||||||||||||||||||||||||
Total quick assets | ||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||
Quick ratio1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Quick Ratio, Competitors2 | ||||||||||||||||||||||||||
Becton, Dickinson & Co. | ||||||||||||||||||||||||||
Boston Scientific Corp. | ||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
Stryker Corp. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (filing date: 2021-02-12), 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29).
1 Q4 2020 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Edwards Lifesciences Corp.’s quick ratio improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020. |
Cash Ratio
Edwards Lifesciences Corp., cash ratio calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Cash and cash equivalents | ||||||||||||||||||||||||||
Short-term investments | ||||||||||||||||||||||||||
Total cash assets | ||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||
Cash ratio1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Cash Ratio, Competitors2 | ||||||||||||||||||||||||||
Becton, Dickinson & Co. | ||||||||||||||||||||||||||
Boston Scientific Corp. | ||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
Stryker Corp. | ||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (filing date: 2021-02-12), 10-Q (filing date: 2020-10-26), 10-Q (filing date: 2020-07-27), 10-Q (filing date: 2020-04-28), 10-K (filing date: 2020-02-14), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-27), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-29), 10-Q (filing date: 2016-04-29).
1 Q4 2020 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Edwards Lifesciences Corp.’s cash ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |